intracellular) BP concentration. Interestingly, the anti-mutagenic effects of BR and BV were most strongly dependent on the bacterial BP absorption exclusively in strain TA98 ( Table 2). An entirely novel observation was also made in that the obtained HPLC spectra (not shown) suggest appearance of BR in plates supplemented with BV, which could imply biliverdin reductase activity in S. typhimurium. The ratio of BV to BR (BV:BR) bacterial

concentrations calculated from HPLC chromatograms (at 1 μmol/plate BV) approximated 4.4:1 in TA98 and 9.6:1 in TA102. This study is the first to report on bacterial BP absorption and its relationship with observed anti-mutagenic effects. When exposed to mutagens, extracellular (plate) BP concentrations negatively Veliparib clinical trial correlated with genotoxicity. Furthermore, testing in TA98 revealed

that BV and BR absorption was more strongly related with anti-mutagenesis, when compared to the anti-mutagenic effect relative to plate concentrations. Previous reports refer to the ability of BPs to act in an anti-oxidant and anti-genotoxic manner in vitro (Asad et al., 2001 and Bulmer et al., 2007) and in vivo (Boon et al., 2012 and Horsfall et al., 2011). Vastly unclear to date however, are the underlying mechanisms of anti-genoxic action. In this context mainly electron scavenging or hydrogen donating capacities (MacLean et al., 2008) and structural interactions between BPs and mutagens (Hayatsu, 1995) are discussed. However, data

on cellular compound absorption Pexidartinib chemical structure are lacking and so far only one recent report on enzymatic BRDT reduction in bacteria (Konickova et al., 2012) exists. Therefore, we explored whether bacterial BP absorption was more closely related to anti-mutagenesis compared to extracellular BP concentrations around S. typhimurium experiencing Low-density-lipoprotein receptor kinase genotoxic stress. In this study, physiologically relevant concentrations of BPs were tested. Un-/conjugated BR is found in the blood, the liver, the intestine (where about 70% are recycled via the enterohepatic cycle), and the urinary tract. In these compartments BR is further metabolised, recycled and/or excreted (Klatskin, 1961). The liver and gut, which are sites of BP accumulation, are at particular risk of genotoxicity due to the absorption, metabolism (Guengerich, 2000 and Turesky et al., 2002) and excretion of mutagens. The abundance of BPs within these organs suggests BPs could exert physiological protection against DNA damage specifically at these sites. Interestingly, BR and BV absorption strongly protected against frame-shift mutation in the TA98 strain. This mutation represents an important mechanism of pathogenesis in gastric and colorectal cancers ( Kim et al., 2010).